Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Moehler

Showing results (131-140 of 218) with videos related to

Pageof 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST studyEric Van Cutsem, Sabine Tejpar, Dirk Vanbeckevoort, et al.
Anti-Cancer Drugs|July 9, 2020
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) studyChristoph Schulz, Volker Heinemann, Kathrin Heinrich, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 3, 2014
Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trialThomas Thomaidis, Annett Maderer, Andrea Formentini, et al.
World Journal of Gastroenterology|July 31, 2007
Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy?Daniel Drescher, Markus Moehler, Ines Gockel, et al.
European Journal of Cancer (Oxford, England : 1990)|October 16, 2012
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)Salah-Eddin Al-Batran, Claudia Pauligk, Nils Homann, et al.
The Lancet. Oncology|April 19, 2013
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trialFlorian Lordick, Yoon-Koo Kang, Hyun-Cheol Chung, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 11, 2018
PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progressionBastian Dörsam, Nina Seiwert, Sebastian Foersch, et al.
European Journal of Cancer (Oxford, England : 1990)|April 4, 2016
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectivesMarkus Moehler, Maike Delic, Katrin Goepfert, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2025
Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysisGiacomo Bregni, Bryan Leurquin, Peggy Giasafaki, et al.
International Journal of Cancer|October 15, 2013
High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancerNaohide Oue, Katsuhiro Anami, Aaron J Schetter, et al.
Pageof 22

Showing results (131-140 of 218) with videos related to

Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST studyEric Van Cutsem, Sabine Tejpar, Dirk Vanbeckevoort, et al.
Anti-Cancer Drugs|July 9, 2020
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) studyChristoph Schulz, Volker Heinemann, Kathrin Heinrich, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 3, 2014
Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trialThomas Thomaidis, Annett Maderer, Andrea Formentini, et al.
World Journal of Gastroenterology|July 31, 2007
Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy?Daniel Drescher, Markus Moehler, Ines Gockel, et al.
European Journal of Cancer (Oxford, England : 1990)|October 16, 2012
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)Salah-Eddin Al-Batran, Claudia Pauligk, Nils Homann, et al.
The Lancet. Oncology|April 19, 2013
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trialFlorian Lordick, Yoon-Koo Kang, Hyun-Cheol Chung, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 11, 2018
PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progressionBastian Dörsam, Nina Seiwert, Sebastian Foersch, et al.
European Journal of Cancer (Oxford, England : 1990)|April 4, 2016
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectivesMarkus Moehler, Maike Delic, Katrin Goepfert, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2025
Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysisGiacomo Bregni, Bryan Leurquin, Peggy Giasafaki, et al.
International Journal of Cancer|October 15, 2013
High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancerNaohide Oue, Katsuhiro Anami, Aaron J Schetter, et al.
Pageof 22